NCT06416930Not yet recruitingPhase 2
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Source: ClinicalTrials.gov · Last updated 16 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- First submitted
- 12 May 2024
- Start date
- 20 Jun 2024
- Primary completion date
- 20 Jun 2027
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Mesothelioma, Lung cancer
- NCT number
- NCT06416930
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 59
- From 20 Jun 2024 to the primary completion date, 20 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.
Other illness
- Known active autoimmune diseases.
- Presence of other uncontrolled serious medical conditions.
Other
- Primary mesothelioma of peritoneum, pericardium and testes
- Active, untreated central nervous system (CNS) metastasis.
Who the study is looking for
- Histologically confirmed advanced or metastatic pleural mesothelioma;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Participants must have previously failed to receive platinum-containing chemotherapy with or without bevacizumab, and have received at most two-line systemic therapy.
- Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
- Adequate haematological, renal and liver function.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.